These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 10824460)
1. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts. Wang J; Nakamoto T; Kasaoka Y; Usui T; Hamada H Hiroshima J Med Sci; 2000 Mar; 49(1):73-82. PubMed ID: 10824460 [TBL] [Abstract][Full Text] [Related]
2. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells. Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497 [TBL] [Abstract][Full Text] [Related]
3. Gene therapy for murine renal cell carcinoma using genetically engineered tumor cells to secrete interleukin-12. Kasaoka Y; Nakamoto T; Wang J; Usui T; Hamada H Hiroshima J Med Sci; 2000 Mar; 49(1):29-35. PubMed ID: 10824454 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma. Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration. Hara I; Nagai H; Miyake H; Yamanaka K; Hara S; Micallef MJ; Kurimoto M; Gohji K; Arakawa S; Ichihashi M; Kamidono S Cancer Gene Ther; 2000 Jan; 7(1):83-90. PubMed ID: 10678360 [TBL] [Abstract][Full Text] [Related]
6. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF. Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934 [TBL] [Abstract][Full Text] [Related]
7. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency. Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574 [TBL] [Abstract][Full Text] [Related]
8. Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect. Liu X; Zhang L; Zhang M; Ma Y; Xu X; Cai Y Chin Med J (Engl); 2000 Feb; 113(2):167-71. PubMed ID: 11775545 [TBL] [Abstract][Full Text] [Related]
9. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma. Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4. Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566 [TBL] [Abstract][Full Text] [Related]
11. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Cayeux S; Beck C; Aicher A; Dörken B; Blankenstein T Eur J Immunol; 1995 Aug; 25(8):2325-31. PubMed ID: 7545119 [TBL] [Abstract][Full Text] [Related]
12. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status. Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic antitumor response to cervical cancer in mice immunized with U14 vaccines transfected with costimulatory B7 gene. Tao G; Hu J; Zou H; Lin Q; Liu F; Wu Y; Sun Q Chin Med J (Engl); 2001 Jun; 114(6):623-7. PubMed ID: 11780440 [TBL] [Abstract][Full Text] [Related]
14. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553 [TBL] [Abstract][Full Text] [Related]
15. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Liu A; Hu P; Khawli LA; Epstein AL Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313 [TBL] [Abstract][Full Text] [Related]
16. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Todo T; Martuza RL; Dallman MJ; Rabkin SD Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154 [TBL] [Abstract][Full Text] [Related]
17. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells. Nishitani MA; Sakai T; Ishii K; Zhang M; Nakano Y; Nitta Y; Miyazaki J; Kanayama HO; Kagawa S; Himeno K Cancer Gene Ther; 2002 Feb; 9(2):156-63. PubMed ID: 11857033 [TBL] [Abstract][Full Text] [Related]
18. Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity. Si SY; Hu PZ; Huang YY; Ye J; Huang Y; Li ZS; Ge W; Li X; Qu P; Zhang XM; Sui YF Biochem Biophys Res Commun; 2006 Aug; 347(1):208-14. PubMed ID: 16814254 [TBL] [Abstract][Full Text] [Related]
19. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352 [TBL] [Abstract][Full Text] [Related]
20. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma. Younes E; Haas GP; Dezso B; Ali E; Maughan RL; Kukuruga MA; Montecillo E; Pontes JE; Hillman GG Cell Immunol; 1995 Oct; 165(2):243-51. PubMed ID: 7553889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]